Presentation of H1-19 report

Ultimovacs invites to presentation of the company’s H1-19 report on 21 August 2019 (08:00) at Oslo Cancer Cluster Innovation Park (Ullernchausséen 64) in Jónas Einarsson Auditorium (2nd floor, entrance 2B).

You can also join us on webcast

More information

News

On 5 August 2019, FIL Limited disclosed additional purchase of shares in Ultimovacs bringing the total holding above 5%.

News

Technology

Ultimovacs is developing a universal cancer vaccine applicable across a broad spectrum of cancer types.

Technology

Clinical studies

Lead product tested in three clinical trials, strong results justifies the initiation of a registration trial.

Clinical studies